BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Simões EA, Carbonell-Estrany X, Fullarton JR, Liese JG, Figueras-Aloy J, Doering G, Guzman J; European RSV Risk Factor Study Group. A predictive model for respiratory syncytial virus (RSV) hospitalisation of premature infants born at 33-35 weeks of gestational age, based on data from the Spanish FLIP Study. Respir Res 2008;9:78. [PMID: 19063742 DOI: 10.1186/1465-9921-9-78] [Cited by in Crossref: 52] [Cited by in F6Publishing: 42] [Article Influence: 3.7] [Reference Citation Analysis]
Number Citing Articles
1 Figueras-Aloy J, Quero-Jiménez J, Fernández-Colomer B, Guzmán-Cabañas J, Echaniz-Urcelay I, Doménech-Martínez E; Grupo IRIS. [Usefulness of different risk factor associations in predicting admissions due to respiratory syncytial virus in premature newborns of 32 to 35 weeks gestation in Spain]. An Pediatr (Barc) 2009;71:47-53. [PMID: 19524492 DOI: 10.1016/j.anpedi.2009.04.010] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
2 Lanari M, Silvestri M, Rossi GA. Palivizumab prophylaxis in ‘late preterm’ newborns. The Journal of Maternal-Fetal & Neonatal Medicine 2010;23:53-5. [DOI: 10.3109/14767058.2010.506757] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
3 Lanari M, Silvestri M, Rossi GA. Respiratory syncytial virus risk factors in late preterm infants. The Journal of Maternal-Fetal & Neonatal Medicine 2009;22:102-7. [DOI: 10.1080/14767050903194438] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
4 Joshi M, Tulloh RM. Respiratory virus prophylaxis in congenital heart disease. Future Cardiol 2018;14:417-25. [PMID: 29877720 DOI: 10.2217/fca-2017-0096] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
5 Mitchell I, Paes B, Lanctot K, Chawla R, Chiu A, Mitchell M, Ojah C, Price A, Seigel S, Symington A. Letters to the Editor. Paediatr Child Health 2015;20:463-4. [PMID: 26744560 DOI: 10.1093/pch/20.8.463] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
6 Houben ML, Olde Nordkamp MJ, Nikkels PG, van der Ent CK, Meyaard L, Bont L. Soluble leukocyte-Associated Ig-like Receptor-1 in amniotic fluid is of fetal origin and positively associates with lung compliance. PLoS One 2013;8:e83920. [PMID: 24386309 DOI: 10.1371/journal.pone.0083920] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
7 Bont L, Blanken M. Viral respiratory burden in moderate-to-late preterm infants. Early Hum Dev 2013;89 Suppl 1:S37-9. [PMID: 23809347 DOI: 10.1016/S0378-3782(13)70012-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
8 Resch B, Kurath S, Manzoni P. Epidemiology of respiratory syncytial virus infection in preterm infants. Open Microbiol J 2011;5:135-43. [PMID: 22262986 DOI: 10.2174/1874285801105010135] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
9 Quinn LA, Shields MD, Groves HE. Respiratory syncytial virus prophylaxis for prevention of recurrent childhood wheeze and asthma: a protocol for a systematic review. Syst Rev 2019;8:333. [PMID: 31856889 DOI: 10.1186/s13643-019-1251-x] [Reference Citation Analysis]
10 Samson L. Prevention of respiratory syncytial virus infection. Paediatr Child Health 2009;14:521-32. [PMID: 20885804 DOI: 10.1093/pch/14.8.521] [Cited by in Crossref: 32] [Cited by in F6Publishing: 23] [Article Influence: 2.9] [Reference Citation Analysis]
11 Carbonell-Estrany X, Fullarton JR, Rodgers-Gray BS, Gooch KL, Vo PG, Figueras-Aloy J. Can we improve the targeting of respiratory syncytial virus (RSV) prophylaxis in infants born 32-35 weeks' gestational age with more informed use of risk factors? J Matern Fetal Neonatal Med 2015;28:1133-41. [PMID: 25048748 DOI: 10.3109/14767058.2014.947573] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
12 Blanken MO, Paes B, Anderson EJ, Lanari M, Sheridan-Pereira M, Buchan S, Fullarton JR, Grubb E, Notario G, Rodgers-Gray BS, Carbonell-Estrany X. Risk scoring tool to predict respiratory syncytial virus hospitalisation in premature infants. Pediatr Pulmonol 2018;53:605-12. [PMID: 29405612 DOI: 10.1002/ppul.23960] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
13 Luo G, Nkoy FL, Gesteland PH, Glasgow TS, Stone BL. A systematic review of predictive modeling for bronchiolitis. Int J Med Inform. 2014;83:691-714. [PMID: 25106933 DOI: 10.1016/j.ijmedinf.2014.07.005] [Cited by in Crossref: 26] [Cited by in F6Publishing: 16] [Article Influence: 3.3] [Reference Citation Analysis]
14 Straňák Z, Saliba E, Kosma P, Posfay-Barbe K, Yunis K, Farstad T, Unnebrink K, van Wyk J, Wegzyn C, Notario G, Kalus S, Campbell FJ. Predictors of RSV LRTI Hospitalization in Infants Born at 33 to 35 Weeks Gestational Age: A Large Multinational Study (PONI). PLoS One 2016;11:e0157446. [PMID: 27310438 DOI: 10.1371/journal.pone.0157446] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 4.2] [Reference Citation Analysis]
15 Borchers AT, Chang C, Gershwin ME, Gershwin LJ. Respiratory syncytial virus--a comprehensive review. Clin Rev Allergy Immunol 2013;45:331-79. [PMID: 23575961 DOI: 10.1007/s12016-013-8368-9] [Cited by in Crossref: 216] [Cited by in F6Publishing: 202] [Article Influence: 27.0] [Reference Citation Analysis]
16 Stensballe LG, Fullarton JR, Carbonell-Estrany X, Simões EA. Population based external validation of a European predictive model for respiratory syncytial virus hospitalization of premature infants born 33 to 35 weeks of gestational age. Pediatr Infect Dis J 2010;29:374-6. [PMID: 20016397 DOI: 10.1097/INF.0b013e3181c810da] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
17 Haerskjold A, Kristensen K, Kamper-Jørgensen M, Nybo Andersen AM, Ravn H, Graff Stensballe L. Risk Factors for Hospitalization for Respiratory Syncytial Virus Infection: A Population-based Cohort Study of Danish Children. Pediatr Infect Dis J 2016;35:61-5. [PMID: 26398871 DOI: 10.1097/INF.0000000000000924] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
18 Anderson EJ, Simões EAF, Buttery JP, Dennehy PH, Domachowske JB, Jensen K, Lieberman JM, Losonsky GA, Yogev R. Prevalence and Characteristics of Human Metapneumovirus Infection Among Hospitalized Children at High Risk for Severe Lower Respiratory Tract Infection. Journal of the Pediatric Infectious Diseases Society 2012;1:212-22. [DOI: 10.1093/jpids/pis069] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 2.5] [Reference Citation Analysis]
19 Carbonell-estrany X, Simões EA, Fullarton JR, Ferdynus C, Gouyon J, The European Rsv Risk Factor Study. Validation of a model to predict hospitalization due to RSV of infants born at 33–35 weeks' gestation. Journal of Perinatal Medicine 2010;38. [DOI: 10.1515/jpm.2010.074] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
20 Abraha HY, Lanctôt KL, Paes B. Risk of respiratory syncytial virus infection in preterm infants: reviewing the need for prevention. Expert Rev Respir Med 2015;9:779-99. [PMID: 26457970 DOI: 10.1586/17476348.2015.1098536] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
21 Figueras Aloy J, Carbonell Estrany X. Recomendaciones de uso de palivizumab para la prevención de la infección por virus respiratorio sincitial en prematuros de 32 1 a 35 0 semanas de gestación. Anales de Pediatría 2010;73:98.e1-4. [DOI: 10.1016/j.anpedi.2010.05.026] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 0.5] [Reference Citation Analysis]
22 Resch B. Respiratory Syncytial Virus Infection in High-risk Infants - an Update on Palivizumab Prophylaxis. Open Microbiol J 2014;8:71-7. [PMID: 25132870 DOI: 10.2174/1874285801408010071] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 3.4] [Reference Citation Analysis]
23 Mosalli R, Abdul Moez AM, Janish M, Paes B. Value of a risk scoring tool to predict respiratory syncytial virus disease severity and need for hospitalization in term infants: Predicting RSV Hospitalization in Term Infants. J Med Virol 2015;87:1285-91. [DOI: 10.1002/jmv.24189] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
24 Carbonell-Estrany X, Fullarton JR, Gooch KL, Gouyon JB, Lanari M, Rodgers-Gray BS, Thwaites RJ, Vo PG, Liese JG. The influence of birth weight amongst 33-35 weeks gestational age (wGA) infants on the risk of respiratory syncytial virus (RSV) hospitalisation: a pooled analysis. J Matern Fetal Neonatal Med 2017;30:134-40. [PMID: 26965584 DOI: 10.3109/14767058.2016.1165199] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
25 Korsten K, Blanken MO, Nibbelke EE, Moons KG, Bont L; Dutch RSV Neonatal Network. Prediction model of RSV-hospitalization in late preterm infants: An update and validation study. Early Hum Dev 2016;95:35-40. [PMID: 26930376 DOI: 10.1016/j.earlhumdev.2016.01.020] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
26 Wegzyn C, Toh LK, Notario G, Biguenet S, Unnebrink K, Park C, Makari D, Norton M. Safety and Effectiveness of Palivizumab in Children at High Risk of Serious Disease Due to Respiratory Syncytial Virus Infection: A Systematic Review. Infect Dis Ther 2014;3:133-58. [PMID: 25297809 DOI: 10.1007/s40121-014-0046-6] [Cited by in Crossref: 47] [Cited by in F6Publishing: 44] [Article Influence: 5.9] [Reference Citation Analysis]
27 Lanari M, Adorni F, Silvestri M, Coscia A, Musicco M; Italian Study Group on Risk Factors for RSV-related Hospitalization. The multicenter Italian birth cohort study on incidence and determinants of lower respiratory tract infection hospitalization in infants at 33 weeks GA or more: preliminary results. Early Hum Dev 2011;87 Suppl 1:S43-6. [PMID: 21277122 DOI: 10.1016/j.earlhumdev.2011.01.009] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
28 Carbonell-Estrany X, Fullarton JR, Gooch KL, Vo PG, Figueras-Aloy J, Lanari M, Gouyon JB, Liese JG. Effects of parental and household smoking on the risk of respiratory syncytial virus (RSV) hospitalisation in late-preterm infants and the potential impact of RSV prophylaxis. J Matern Fetal Neonatal Med 2013;26:926-31. [PMID: 23379728 DOI: 10.3109/14767058.2013.765850] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
29 Blanken MO, Koffijberg H, Nibbelke EE, Rovers MM, Bont L; Dutch RSV Neonatal Network. Prospective validation of a prognostic model for respiratory syncytial virus bronchiolitis in late preterm infants: a multicenter birth cohort study. PLoS One 2013;8:e59161. [PMID: 23554987 DOI: 10.1371/journal.pone.0059161] [Cited by in Crossref: 41] [Cited by in F6Publishing: 37] [Article Influence: 4.6] [Reference Citation Analysis]
30 Manzoni P, Paes B, Resch B, Mejias A, Ramilo O, Carbonell-estrany X, Bont L. High risk for RSV bronchiolitis in late preterms and selected infants affected by rare disorders: a dilemma of specific prevention. Early Human Development 2012;88:S34-41. [DOI: 10.1016/s0378-3782(12)70012-9] [Cited by in Crossref: 21] [Cited by in F6Publishing: 8] [Article Influence: 2.1] [Reference Citation Analysis]
31 Houben ML, Rovers MM, Wilbrink B, Belderbos ME, Bloemen-Carlier EM, Visser GH, Kimpen JL, Bont L. High concentrations of amniotic fluid proinflammatory cytokines in healthy neonates are associated with low risk of respiratory syncytial virus bronchiolitis. Pediatr Infect Dis J 2012;31:931-4. [PMID: 22699404 DOI: 10.1097/INF.0b013e31826366e3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
32 Drazdienė N, Tamelienė R, Kviluna D, Saik P, Saik E, Zaikauskienė J. Hospitalisation of late preterm infants due to lower respiratory tract infections in Lithuania, Latvia, and Estonia: incidence, disease severity, and risk factors. Acta Med Litu 2018;25:76-85. [PMID: 30210241 DOI: 10.6001/actamedica.v25i2.3760] [Reference Citation Analysis]
33 Sheridan-Pereira M, Murphy J, Sloan J, Crispino G, Leahy A, Corcoran JD, Dempsey E, Elnazir B, Gavin P, Sharif F, Gul R, Satas S, Murphy J, Gormally S, Shanaa I, Waldron D, Mc Mahon P, Carson J, Blanken M, Bont L, Paes B. Respiratory Syncytial Virus Preterm (32-36 Completed Weeks of Gestation) Risk Estimation Measure for RSV Hospitalization in Ireland: A Prospective Study. Pediatr Infect Dis J 2016;35:19-24. [PMID: 26379160 DOI: 10.1097/INF.0000000000000918] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
34 Pike KC, Lucas JS. Respiratory consequences of late preterm birth. Paediatr Respir Rev 2015;16:182-8. [PMID: 25554628 DOI: 10.1016/j.prrv.2014.12.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 19] [Article Influence: 0.9] [Reference Citation Analysis]
35 Simões EAF, Carbonell-estrany X, Fullarton JR, Rossi GA, Barberi I, Lanari M. European risk factors' model to predict hospitalization of premature infants born 33–35 weeks' gestational age with respiratory syncytial virus: validation with Italian data. The Journal of Maternal-Fetal & Neonatal Medicine 2010;24:152-7. [DOI: 10.3109/14767058.2010.482610] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
36 Ryan VMJ, Langley JM, Dodds L, Andreou P. Estimating Respiratory Syncytial Virus-associated Hospitalization in the First Year of Life Among Infants Born at 32–35 Weeks of Gestation. Pediatric Infectious Disease Journal 2016;35:851-5. [DOI: 10.1097/inf.0000000000001186] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
37 Paes BA, Mitchell I, Banerji A, Lanctôt KL, Langley JM. A decade of respiratory syncytial virus epidemiology and prophylaxis: translating evidence into everyday clinical practice. Can Respir J 2011;18:e10-9. [PMID: 21499597 DOI: 10.1155/2011/493056] [Cited by in Crossref: 43] [Cited by in F6Publishing: 40] [Article Influence: 4.3] [Reference Citation Analysis]
38 Butt ML, Symington A, Janes M, Elliott L, Steele S, Paes BA. The impact of prophylaxis on paediatric intensive care unit admissions for RSV infection: a retrospective, single-centre study. Eur J Pediatr 2011;170:907-13. [PMID: 21174120 DOI: 10.1007/s00431-010-1376-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
39 Sommer C, Resch B, Simões EA. Risk factors for severe respiratory syncytial virus lower respiratory tract infection. Open Microbiol J 2011;5:144-54. [PMID: 22262987 DOI: 10.2174/1874285801105010144] [Cited by in Crossref: 109] [Cited by in F6Publishing: 107] [Article Influence: 9.9] [Reference Citation Analysis]
40 Figueras-Aloy J, Manzoni P, Paes B, Simões EA, Bont L, Checchia PA, Fauroux B, Carbonell-Estrany X. Defining the Risk and Associated Morbidity and Mortality of Severe Respiratory Syncytial Virus Infection Among Preterm Infants Without Chronic Lung Disease or Congenital Heart Disease. Infect Dis Ther 2016;5:417-52. [PMID: 27628014 DOI: 10.1007/s40121-016-0130-1] [Cited by in Crossref: 40] [Cited by in F6Publishing: 40] [Article Influence: 6.7] [Reference Citation Analysis]
41 Paes B, Mitchell I, Li A, Lanctôt KL. Respiratory hospitalizations and respiratory syncytial virus prophylaxis in special populations. Eur J Pediatr 2012;171:833-41. [PMID: 22203430 DOI: 10.1007/s00431-011-1654-8] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 3.0] [Reference Citation Analysis]
42 Jourdain M, Benchaib M, Ploin D, Gillet Y, Javouhey E, Horvat C, Massoud M, Butin M, Claris O, Lina B, Casalegno J; on behalf of the VRS study group in Lyon. Identifying the Target Population for Primary Respiratory Syncytial Virus Two-Step Prevention in Infants: Normative Outcome of Hospitalisation Assessment for Newborns (NOHAN). Vaccines 2022;10:729. [DOI: 10.3390/vaccines10050729] [Reference Citation Analysis]
43 Resch B, Paes B. Are late preterm infants as susceptible to RSV infection as full term infants? Early Hum Dev 2011;87 Suppl 1:S47-9. [PMID: 21276672 DOI: 10.1016/j.earlhumdev.2011.01.010] [Cited by in Crossref: 31] [Cited by in F6Publishing: 24] [Article Influence: 2.8] [Reference Citation Analysis]
44 Trento A, Casas I, Calderón A, Garcia-Garcia ML, Calvo C, Perez-Breña P, Melero JA. Ten years of global evolution of the human respiratory syncytial virus BA genotype with a 60-nucleotide duplication in the G protein gene. J Virol 2010;84:7500-12. [PMID: 20504933 DOI: 10.1128/JVI.00345-10] [Cited by in Crossref: 122] [Cited by in F6Publishing: 75] [Article Influence: 10.2] [Reference Citation Analysis]
45 Paes B, Mitchell I, Li A, Lanctôt KL; CARESS Investigators. A comparative study of respiratory syncytial virus (RSV) prophylaxis in premature infants within the Canadian Registry of Palivizumab (CARESS). Eur J Clin Microbiol Infect Dis 2012;31:2703-11. [PMID: 22546928 DOI: 10.1007/s10096-012-1617-7] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]